Akhil Santhosh, Medical Oncologist at AIIMS Delhi, shared an article by Fatima Cardoso on X:
“Primary efficacy and safety results from the AMALEE trial evaluating 600 vs 400 mg starting doses of first-line ribociclib in patients with advanced BC.
400mg ribo has a better side effect profile but failed to meet non inferiority vs 600mg.”
Abstract PD17-12: Primary efficacy and safety results from the AMALEE trial evaluating 600 mg vs 400 mg starting doses of first-line ribociclib in patients with HR+/HER2− advanced breast cancer.
Authors: Fatima Cardoso, et al.
More posts featuring Akhil Santhosh.